First Time Loading...

Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 29.97 USD 0.88% Market Closed
Updated: Jul 21, 2024
Have any thoughts about
Pfizer Inc?
Write Note

Wall Street
Price Targets

PFE Price Targets Summary
Pfizer Inc

Wall Street analysts forecast PFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PFE is 32.09 USD with a low forecast of 27.27 USD and a high forecast of 47.25 USD.

Lowest
Price Target
27.27 USD
9% Downside
Average
Price Target
32.09 USD
7% Upside
Highest
Price Target
47.25 USD
58% Upside

PFE Last Price Targets
Pfizer Inc

The latest public price target was made on Jul 10, 2024 by Carter Gould from Barclays , who expects PFE stock to rise by 0% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Carter Gould
Barclays
30 USD
Upside 0%
1 week ago
Jul 10, 2024
Pfizer price target raised to $30 from $28 at Barclays
TheFly
Evan Seigerman
BMO Capital
36 USD
Upside 20%
1 month ago
May 22, 2024
Pfizer cost reduction program a positive for the shares, says BMO
TheFly
Louise Chen
Cantor Fitzgerald
45 USD
Upside 50%
5 months ago
Feb 14, 2024
Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga
Thomas Yeh
Morgan Stanley
20 USD
Downside 33%
7 months ago
Dec 14, 2023
Harmonic To Rally Over 80%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga
Terence Flynn
Morgan Stanley
37 USD
Upside 23%
7 months ago
Nov 27, 2023
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
Benzinga
Unknown Analyst
Morgan Stanley
45 USD
Upside 50%
1 year ago
Feb 1, 2023
Morgan Stanley Maintains Equal-Weight on Pfizer, Lowers Price Target to $45
Benzinga
Unknown Analyst
Barclays
44 USD
Upside 47%
1 year ago
Feb 1, 2023
Barclays Maintains Equal-Weight on Pfizer, Lowers Price Target to $44
Benzinga
Unknown Analyst
Credit Suisse
50 USD
Upside 67%
1 year ago
Feb 1, 2023
Credit Suisse Maintains Outperform on Pfizer, Lowers Price Target to $50
Benzinga
Unknown Analyst
Leerink Partners
48 USD
Upside 60%
1 year ago
Feb 1, 2023
SVB Leerink Maintains Market Perform on Pfizer, Lowers Price Target to $48
Benzinga
Unknown Analyst
Atlantic Equities
46 USD
Upside 53%
1 year ago
Feb 1, 2023
Atlantic Equities Maintains Neutral on Pfizer, Lowers Price Target to $46
Benzinga
Show More Price Targets
Show Less Price Targets
Carter Gould
Barclays
Price Target 30 USD
Upside/Downside 0%
View Source
Evan Seigerman
BMO Capital
Price Target 36 USD
Upside/Downside 20%
View Source
Louise Chen
Cantor Fitzgerald
Price Target 45 USD
Upside/Downside 50%
View Source
Thomas Yeh
Morgan Stanley
Price Target 20 USD
Upside/Downside 33%
View Source
Terence Flynn
Morgan Stanley
Price Target 37 USD
Upside/Downside 23%
View Source
Unknown Analyst
Morgan Stanley
Price Target 45 USD
Upside/Downside 50%
View Source
Unknown Analyst
Barclays
Price Target 44 USD
Upside/Downside 47%
View Source
Unknown Analyst
Credit Suisse
Price Target 50 USD
Upside/Downside 67%
View Source
Unknown Analyst
Leerink Partners
Price Target 48 USD
Upside/Downside 60%
View Source
Unknown Analyst
Atlantic Equities
Price Target 46 USD
Upside/Downside 53%
View Source
Show More Price Targets
Show Less Price Targets
Pfizer Inc Competitors:
Price Targets
086450
Dongkook Pharmaceutical Co Ltd
34% Upside
4507
Shionogi & Co Ltd
16% Upside
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
6% Upside
214370
Caregen Co Ltd
2% Upside
002399
Shenzhen Hepalink Pharmaceutical Group Co Ltd
36% Downside
002020
Zhejiang Jingxin Pharmaceutical Co Ltd
23% Upside
TUB
Financiere de Tubize SA
25% Upside
002390
Guizhou Xinbang Pharmaceutical Co Ltd
123% Upside

Revenue
Forecast

Revenue Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 3 years is 3%.

2%
Past Growth
3%
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 3 years is 17%.

-1%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-22%
Average Miss

Net Income
Forecast

Net Income Estimate
Pfizer Inc

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 3 years is 99%.

-14%
Past Growth
99%
Estimated Growth
Estimates Accuracy
-35%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PFE's stock price target?
Price Target
32.09 USD

According to Wall Street analysts, the average 1-year price target for PFE is 32.09 USD with a low forecast of 27.27 USD and a high forecast of 47.25 USD.

What is Pfizer Inc's Revenue forecast?
Projected CAGR
3%

For the last 8 years the compound annual growth rate for Pfizer Inc's revenue is 2%. The projected CAGR for the next 3 years is 3%.

What is Pfizer Inc's Operating Income forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Pfizer Inc's operating income is -1%. The projected CAGR for the next 3 years is 17%.

What is Pfizer Inc's Net Income forecast?
Projected CAGR
99%

For the last 8 years the compound annual growth rate for Pfizer Inc's net income is -14%. The projected CAGR for the next 3 years is 99%.